Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. - Wikidata - wikimedia - TriplyDB

Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.

Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.

http://www.wikidata.org/entity/Q37614181

about

Micro-NMR for rapid molecular analysis of human tumor samples Current targeted therapies in the treatment of advanced colorectal cancer: a review Identifying potential indicators to measure the outcome of translational cancer research: a mixed methods approach Identification of direct target engagement biomarkers for kinase-targeted therapeutics Molecular biomarker analyses using circulating tumor cells Circulating Tumor Cell Isolation and Analysis.Enhancing reproducibility in cancer drug screening: how do we move forward?Mutational landscapes of tongue carcinoma reveal recurrent mutations in genes of therapeutic and prognostic relevance.Biomarker discovery and clinical proteomics.Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science Can Functional Magnetic Resonance Imaging Improve Success Rates in CNS Drug Discovery?DNA repair and personalized breast cancer therapy Pharmacodynamic modelling of biomarker data in oncology.Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab.Kinotypes: stable species- and individual-specific profiles of cellular kinase activity.Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures.Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort.Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials.Isoform level expression profiles provide better cancer signatures than gene level expression profiles.Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.Reporting practices of pharmacodynamic studies involving invasive research procedures in cancer trials.The interaction between prognostic and pharmacodynamic biomarkers.Prognostic role of phospho-PRAS40 (Thr246) expression in gastric cancer Early reduction in tumour [18F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone.How informatics can potentiate precompetitive open-source collaboration to jump-start drug discovery and development.Molecular imaging and targeted therapies.Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs.Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.Organ-specific markers in circulating tumor cell screening: an early indicator of metastasis-capable malignancy.Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers Discovery of small molecule cancer drugs: successes, challenges and opportunities.Re-overcoming barriers in translating biomarkers to clinical practice.Ex vivo culture of human prostate tissue and drug development.A matrix approach to guide IHC-based tissue biomarker development in oncology drug discovery.Impact of biomarkers on clinical trial risk.Utility of free and total target measurements as target engagement and efficacy biomarkers in biotherapeutic development--opportunities and challenges.Cancer diagnostics: The journey from histomorphology to molecular profiling.Phosphorylated ribosomal S6 (p-rpS6) as a post-treatment indicator of HER2 signalling targeted drug resistance.Restoration of altered somatosensory cortical representation with spinal cord stimulation therapy in a patient with complex regional pain syndrome: a magnetoencephalography case study.Fit-for-purpose biomarker immunoassay qualification and validation: three case studies.

P2860

Q24603587-C3868EE2-6F6B-40AF-AF4C-A01EDBE669A0 Q26740067-64B1C2D1-F178-4AC9-8257-3EE0D8536F7D Q27303882-CFBDF757-ACDC-435E-842C-3B207296440E Q28477593-4BCEE019-6F60-4390-AB5F-2C88A58769CF Q28749394-48926FBF-27C7-466A-B827-76ECE6E8E52D Q30358229-0AE33A6F-F86C-4E0B-834F-CC89CE1DCCC8 Q30405622-1E05FE99-EC97-449B-A2B2-DE934EF0F1BB Q30665308-6CDDBC09-5014-4112-B190-D033F2E875B3 Q33655101-D0AEB130-ECDC-4329-A8D5-EA64F7B3A7B9 Q33746514-3D7E7183-E5BB-40D4-AE5E-1ADC9A17DD48 Q33963735-D95415C7-2F9B-4FD7-B010-343F6549F759 Q34234936-DEC2CC96-6E73-4F03-B56D-27F68675B478 Q34241935-4EF932C1-31BC-41BB-8CCD-33A7279C48F6 Q35050195-3FFD8289-AC5D-447E-9F27-1366F518F32B Q35061942-FE93FCC4-0CBC-4EFF-8411-FBB7A4E9DC38 Q36181578-A05A3E77-4620-4ED6-BB93-0CA24940417D Q36910794-90EE6341-4D97-4820-A64E-B47D75979597 Q36914483-09AD3527-CA2F-4920-B8E3-E57C8D6A2E91 Q36997815-6539DA76-4BE5-4DF8-B247-9CB46623ADED Q37094837-8CC47280-33E7-41B2-8CEE-46F2AA6D489F Q37111197-D7CDE8DA-6DC4-484D-B4C1-1038DC99FE97 Q37214321-78D6DE3E-350B-4CAA-8632-8045A9546973 Q37636833-DC6CC423-A90C-4211-8BD0-01D43A96C196 Q37638896-FA4B24C3-03AD-43D0-9A34-A1DE2DC6C4E0 Q37726976-2C915AE4-5194-4638-ACF8-15D2A55FE61C Q37732704-99CD555C-A343-4762-8042-758C6E9FBE43 Q37798159-D3541E68-2DFB-40EF-94E0-E81B166B23D2 Q37809871-02A6BA68-EC81-48F6-BD20-5A28D1900291 Q37898107-917A99D7-D154-4063-8C5C-6B5415BC3CBA Q37902873-BDD31E3E-EFC4-4038-9650-FE8D783A2FFE Q37996113-B837623A-3C2F-46C2-89D3-36650F072D1D Q38088713-F926FF1A-057A-455C-BF42-864595CF8BEC Q38113460-D4CD7545-D483-46B9-8ACC-333A100FB178 Q38137016-6747C982-5BC6-4107-88ED-DF9339425391 Q38148601-60D408C5-3292-4695-85B1-D42F998EA0C2 Q38364466-F7C5F36A-16BA-4F92-B7EC-7C7926F21844 Q38559476-A05B2130-614B-41C8-8170-E364B7B9A875 Q38838851-9D6BFCC2-E7E4-45B7-9E0D-26642189FB6C Q39231769-DA75C730-DD1D-4E27-B022-C0ED8F7551BB Q39315816-DC1758FC-2914-45AA-841F-8FB67F2C4CF6

P2860

Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.

http://www.wikidata.org/entity/Q37614181

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.

@en

Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.

@nl

type

label

Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.

@en

Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.

@nl

prefLabel

Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.

@en

Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.

@nl

P1433

Q37614181-F31760D1-5DC1-4FFB-B0C7-6B2819556D1E

P1476

Q37614181-8A4A61E3-8050-4772-B25D-9161748EC6D7

P2093

Q37614181-03099D7A-9CC6-49C8-A833-78EA260123CC

Q37614181-3B9B1BE3-72FA-429E-B3C5-5B626CEA3880

Q37614181-60C712B4-0D31-4CD8-8B61-2B9565029856

Q37614181-A277297D-45A9-4B37-A653-6DBFD082C558

Q37614181-C80ADE0E-D804-4E83-9613-46450061C432

Q37614181-F282589A-B2F1-422F-A2D3-25EE11F64138

P304

Q37614181-D144A55F-A6E3-439C-A682-33B716F55424

P31

Q37614181-B5B139FE-31BE-49B5-B389-0BB2F4E67CE6

P356

Q37614181-FF7610D0-D51B-44C3-887D-140E50DD2A76

P433

Q37614181-76C369C0-1072-4E9B-87B1-489B3AE4A61C

P478

Q37614181-887B7EF3-B292-4DE5-AD1B-5D56149AA5C4

P50

Q37614181-DFDB6C6B-8C91-4850-A5D1-A5DB2BC0482B

P577

Q37614181-9D6663F8-D8F4-4371-B31D-05C34008D505

P698

Q37614181-093A769D-60B9-4CEF-BBA8-F095B1654D16

P921

Q37614181-CE81724C-CD11-4D08-A2AD-F8F1A18BED23

P356

PPO.0B013E3181BD0445

P1433

The Cancer Journal

P1476

Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.

@en

P2093

Daniel S W Tan

http://www.w3.org/2001/XMLSchema#string

George V Thomas

http://www.w3.org/2001/XMLSchema#string

Johann S de Bono

http://www.w3.org/2001/XMLSchema#string

Michelle D Garrett

http://www.w3.org/2001/XMLSchema#string

Stan B Kaye

http://www.w3.org/2001/XMLSchema#string

Udai Banerji

http://www.w3.org/2001/XMLSchema#string

P304

406-420

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/PPO.0B013E3181BD0445

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19826361

http://www.w3.org/2001/XMLSchema#string

P921